Compare
Bio Essence Corp vs Rani Therapeutics Holdings, Inc. vs Northwest Biotherapeutics Inc vs China SXT Pharmaceuticals, Inc.
| Latest fiscal year | Bio Essence Corp BIOE | Rani Therapeutics Holdings, Inc. RANI | Northwest Biotherapeutics Inc NWBO | China SXT Pharmaceuticals, Inc. SXTC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $1.90M | $1.63M | $1.38M | $1.14M |
| Revenue growth (YoY) | +485.8% | +58.9% | -0.3% | -34.6% |
| Gross margin | 75.3% | n/a | n/a | 21.9% |
| Operating margin | 47.4% | n/m | n/m | -625.9% |
| Net margin | 47.2% | n/m | n/m | -545.2% |
| Net income | $896.2K | -$40.95M | -$60.16M | -$6.21M |
| EPS (Diluted) | n/a | -$0.45 | -$0.04 | -$9.13 |
| Operating cash flow | $1.57M | -$18.71M | -$44.76M | -$4.02M |
| Free cash flow | n/a | -$18.80M | -$46.27M | n/a |
| Cash & equivalents | n/a | $18.62M | $3.04M | $28.18M |
| Total assets | $422.5K | $58.62M | $81.29M | $34.75M |
| Total liabilities | $2.50M | $17.11M | $128.86M | $5.05M |
| Shareholders' equity | -$2.07M | $33.01M | -$60.28M | $29.71M |
| Return on year-end equity | n/a | -124.1% | n/a | -20.9% |
| Shares outstanding | 38.01M | n/a | 1.56B | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Bio Essence Corp | Rani Therapeutics Holdings, Inc. | Northwest Biotherapeutics Inc | China SXT Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $1.90M Ended 2025-12-31 | $1.63M Ended 2025-12-31 | $1.38M Ended 2025-12-31 | $1.14M Ended 2026-03-31 |
| 1 year earlier | $323.9K Ended 2024-12-31 | $1.03M Ended 2024-12-31 | $1.38M Ended 2024-12-31 | $1.74M Ended 2025-03-31 |
| 2 years earlier | $551.5K Ended 2023-12-31 | $0 Ended 2023-12-31 | $1.93M Ended 2023-12-31 | $1.93M Ended 2024-03-31 |
| 3 years earlier | $621.6K Ended 2022-12-31 | $0 Ended 2022-12-31 | $1.68M Ended 2022-12-31 | $1.97M Ended 2023-03-31 |
| 4 years earlier | $888.0K Ended 2021-12-31 | $2.72M Ended 2021-12-31 | $1.00M Ended 2021-12-31 | $2.60M Ended 2022-03-31 |